The role of the liver in serum-induced hypercoagulability.
作者信息
Deykin D
出版信息
J Clin Invest. 1966 Feb;45(2):256-63. doi: 10.1172/JCI105338.
Abstract
摘要
相似文献
1
The role of the liver in serum-induced hypercoagulability.
J Clin Invest. 1966 Feb;45(2):256-63. doi: 10.1172/JCI105338.
2
ACTIVATION PRODUCT, FACTOR IX, SERUM THROMBOTIC ACCELERATOR ACTIVITY, AND SERUM-INDUCED THROMBOSIS.
J Clin Invest. 1964 Feb;43(2):160-6. doi: 10.1172/JCI104900.
3
STASIS THROMBI INDUCED BY BACTERIAL ENDOTOXIN.
Circ Res. 1964 Jun;14:486-93. doi: 10.1161/01.res.14.6.486.
4
[Clinical and experimental studies on the contact factor. II. Experimental studies on the thrombotic activity of activation product].
Nihon Ketsueki Gakkai Zasshi. 1968 Dec;31(7):1155-64.
5
Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis.
Clin Gastroenterol Hepatol. 2012 Jan;10(1):72-8. doi: 10.1016/j.cgh.2011.09.010. Epub 2011 Sep 23.
6
[Technic of liver perfusion].
Z Exp Chir. 1971;4(4):224-7.
7
Withering heights--high factor levels a new thrombotic risk?
CAP Today. 2000 Nov;14(11):1, 26-8, 30 passim.
8
Further studies on the activation of factor IX by activated factor XI.
Thromb Diath Haemorrh Suppl. 1965;17:15-22.
9
Coagulation abnormalities in cirrhotic patients with portal vein thrombosis.
Clin Lab. 2007;53(9-12):583-9.
10
Thrombogenicity of factor IX complex: in vivo investigation.
Dev Biol Stand. 1987;67:149-55.
引用本文的文献
1
Factor VIIa binding and internalization in hepatocytes.
J Thromb Haemost. 2005 Oct;3(10):2264-73. doi: 10.1111/j.1538-7836.2005.01542.x.
2
Metabolism of fibrinogen in cirrhosis of the liver.
J Clin Invest. 1971 Aug;50(8):1690-701. doi: 10.1172/JCI106658.
3
Local and systemic factors in the pathogenesis of thrombosis.
Calif Med. 1970 Mar;112(3):31-40.
4
Progress in disseminated intravascular coagulation.
Calif Med. 1969 Sep;111(3):186-98 contd.
5
[Proceedings: Physiology of the coagulation mechanism (author's transl)].
Langenbecks Arch Chir. 1973;334:763-9. doi: 10.1007/BF01286642.
6
Impaired coagulation in the bleeding of chronic liver disease.
J R Coll Physicians Lond. 1973 Oct;8(1):79-86.
7
[Endogenous inhibitors of fibrinolytic activity in liver cirrhosis (author's transl)].
Klin Wochenschr. 1973 Dec 1;51(23):1170-2. doi: 10.1007/BF01468567.
8
Intravascular fibrin deposits, hepatic infarcts and thrombocytopenia in parent/F mouse chimeras with host-versus-graft syndrome.
Am J Pathol. 1975 Apr;79(1):131-46.
9
Fulminant hepatic failure secondary to congestive heart failure.
Am J Dig Dis. 1976 Oct;21(10):895-900. doi: 10.1007/BF01072084.
10
Dysfibrinogenemia associated with liver disease.
J Clin Invest. 1977 Jul;60(1):89-95. doi: 10.1172/JCI108773.
本文引用的文献
1
Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis.
J Clin Invest. 1955 Apr;34(4):647-51. doi: 10.1172/JCI103114.
2
ROLES OF SURFACE FACTOR AND A PLASMA INHIBITORY ACTIVITY (ANTI-SF) DURING EXPERIMENTAL THROMBOSIS IN RABBITS.
Thromb Diath Haemorrh. 1964 Dec 31;12:489-504.
3
ACTIVATION PRODUCT, FACTOR IX, SERUM THROMBOTIC ACCELERATOR ACTIVITY, AND SERUM-INDUCED THROMBOSIS.
J Clin Invest. 1964 Feb;43(2):160-6. doi: 10.1172/JCI104900.
4
The relation of factors XII, XI, and IX to hypercoagulable states.
Thromb Diath Haemorrh. 1963 Apr 15;9:90-101.
5
Studies on the in vivo behavior of blood coagulation product I in rats.
Thromb Diath Haemorrh. 1962 Nov 15;8:276-85.
6
Serum-induced thrombosis. Studies of its induction, and evolution under controlled conditions in vivo.
Circulation. 1959 Nov;20:864-74. doi: 10.1161/01.cir.20.5.864.
7
Biologic assay of a thrombosis-inducing activity in human serum.
J Appl Physiol. 1959 Nov;14:943-6. doi: 10.1152/jappl.1959.14.6.943.
8
Effect of intravenous blood thromboplastin intermediates on clotting in rats.
Am J Physiol. 1958 Oct;195(1):77-80. doi: 10.1152/ajplegacy.1958.195.1.77.
9
A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases.
Am J Clin Pathol. 1957 Jul;28(1):56-63. doi: 10.1093/ajcp/28.1.56.
Zotero 插件